<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1688-0420</journal-id>
<journal-title><![CDATA[Revista Uruguaya de Cardiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev.Urug.Cardiol.]]></abbrev-journal-title>
<issn>1688-0420</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Uruguaya de Cardiología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1688-04202019000300333</article-id>
<article-id pub-id-type="doi">10.29277/cardio.34.3.25</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Manejo de la intolerancia a estatinas: un desafío cotidiano en la práctica clínica]]></article-title>
<article-title xml:lang="en"><![CDATA[Management of statin intolerance: a daily challenge in clinical practice]]></article-title>
<article-title xml:lang="pt"><![CDATA[Manejo da intolerância à estatina: um desafio diário na prática clínica]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Miranda]]></surname>
<given-names><![CDATA[Natalia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Católica del Uruguay  ]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2019</year>
</pub-date>
<volume>34</volume>
<numero>3</numero>
<fpage>333</fpage>
<lpage>355</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_arttext&amp;pid=S1688-04202019000300333&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_abstract&amp;pid=S1688-04202019000300333&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_pdf&amp;pid=S1688-04202019000300333&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen: La enfermedad cardiovascular ateromatosa continúa siendo la primera causa de morbimortalidad en el mundo a pesar de los avances tanto en las estrategias de cardiología intervencionista, como en el abordaje integral de los factores de riesgo cardiovascular. Las estatinas constituyen los fármacos de elección para el manejo del riesgo cardiovascular y la mayoría de las dislipemias. Existe evidencia robusta acerca de la reducción de eventos cardiovasculares mayores, cuyo beneficio es dosis dependiente. De esta forma un gran número de personas tienen indicación de estatinas, existiendo un porcentaje próximo a 20% de pacientes que refieren no tolerarlas. Sin embargo, tan solo un 5% de los que reciben estatinas son realmente intolerantes. Dado su probado beneficio, los clínicos deben asegurarse de que los efectos adversos que manifiesta el paciente estén realmente asociados a estas drogas. De otro modo se estaría privando a algunos pacientes, en forma injustificada, de la reducción de la morbimortalidad asociada al uso de estatinas.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Summary: Atherosclerotic cardiovascular disease remains the leading cause of morbidity and mortality in the world despite advances in both interventional cardiology strategies and comprehensive approach to cardiovascular risk factors. Statins constitute the drugs of choice for the management of cardiovascular risk and most dyslipidemias. There is robust evidence about the reduction of major cardiovascular events, whose benefit is dose dependent. In this way a large number of people have an indication of statins, but a percentage close to 20% report to be intolerant. Nevertheless only 5% of the patients treated with statins, are real intolerant. Clinicians should confirm that the adverse effects are really associated with these drugs, to avoid losing the benefit before discontinuation.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo: A doença cardiovascular ateromatosa ainda é a principal causa de morbidade e mortalidade do mundo, apesar dos avanços nas estratégias de cardiologia intervencionista, tais como a abordagem abrangente de fatores de risco cardiovascular. As estatinas são drogas de escolha para a gestão de risco cardiovascular e a maioria das dislipidemias. Há evidências robustas sobre a redução de grandes eventos cardiovasculares maiores cujo benefício é dose-dependente. Desta forma, um grande número de pessoas tem indicação de estatinas, há uma porcentagem cerca de 20% dos pacientes, referindo-se a não tolerá-las. No entanto, apenas 5% de pessoas tratadas são realmente intolerantes. Dado o benefício comprovado das estatinas, os clínicos devem assegurar os efeitos adversos que o paciente se manifesta são realmente associados com estas drogas. Caso contrário o benefício claro na redução da morbidade e mortalidade se retira de maneira injustificada.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Inhibidores de Hidroximetilglutaril-CoA Reductasa]]></kwd>
<kwd lng="es"><![CDATA[Intolerancia]]></kwd>
<kwd lng="es"><![CDATA[Efectos adversos asociados a estatinas]]></kwd>
<kwd lng="en"><![CDATA[Hydroxymethylglutaryl-CoA Reductase Inhibitors]]></kwd>
<kwd lng="en"><![CDATA[Intolerance]]></kwd>
<kwd lng="en"><![CDATA[Adverse effects associated with statins]]></kwd>
<kwd lng="pt"><![CDATA[Inibidores de Hidroximetilglutaril-CoA Redutase]]></kwd>
<kwd lng="pt"><![CDATA[Intolerância]]></kwd>
<kwd lng="pt"><![CDATA[Efeitos adversos associados às estatinas]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosenson]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Baker]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Jacobson]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kopecky]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Parker]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An assessment by the Statin Muscle Safety Task Force: 2014 update]]></article-title>
<source><![CDATA[J Clin Lipidol]]></source>
<year>2014</year>
<volume>8</volume>
<numero>3^sSuppl</numero>
<issue>3^sSuppl</issue>
<supplement>Suppl</supplement>
<page-range>S58-71</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Algharably]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Filler]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenfeld]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Grabowski]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kreutz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Statin intolerance: a question of definition]]></article-title>
<source><![CDATA[Expert Opin Drug Saf]]></source>
<year>2017</year>
<volume>16</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>55-63</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cho]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jeong]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Sim]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of postdischarge statin withdrawal on long-term outcomes in patients with acute myocardial infarction]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2015</year>
<volume>115</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-7</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Serban]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Colantonio]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Manthripragada]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Monda]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Bittner]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Banach]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2017</year>
<volume>69</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1386-95</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Banach]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Serban]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Discussion around statin discontinuation in older adults and patients with wasting diseases]]></article-title>
<source><![CDATA[J Cachexia, Sarcopenia and Muscle]]></source>
<year>2016</year>
<volume>7</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>396-9</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Polonsky]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Miedema]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Khera]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kosinski]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kuvin]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2019</year>
<volume>73</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>3210-27</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mancini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Baker]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bergeron]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Fitchett]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Frohlich]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Genest]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Consensus Working Group Update (2016)]]></article-title>
<source><![CDATA[Can J Cardiol]]></source>
<year>2016</year>
<volume>32</volume>
<numero>7^sSuppl</numero>
<issue>7^sSuppl</issue>
<supplement>Suppl</supplement>
<page-range>S35-65</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guyton]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bays]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Grundy]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Jacobson]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An assessment by the Statin Intolerance Panel: 2014 update]]></article-title>
<source><![CDATA[J Clin Lipidol]]></source>
<year>2014</year>
<volume>8</volume>
<numero>3^sSuppl</numero>
<issue>3^sSuppl</issue>
<supplement>Suppl</supplement>
<page-range>S72-81</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jacobson]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ito]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Maki]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Orringer]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bays]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1, executive summary]]></article-title>
<source><![CDATA[J Clin Lipidol]]></source>
<year>2014</year>
<volume>8</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>473-88</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Olshansky]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Placebo and nocebo in cardiovascular health: implications for healthcare, research, and the doctor-patient relationship]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2007</year>
<volume>49</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>415-21</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Banach]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rizzo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Toth]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Farnier]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Davidson]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Rasadi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Statin intolerance: an attempt at a unified definition. Position paper from an International Lipid Expert Panel]]></article-title>
<source><![CDATA[Expert Opin Drug Saf]]></source>
<year>2015</year>
<volume>14</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>935-55</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cannon]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Blazing]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Giugliano]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[McCagg]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[White]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Theroux]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ezetimibe added to statin therapy after acute coronary syndromes]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2015</year>
<volume>372</volume>
<numero>25</numero>
<issue>25</issue>
<page-range>2387-97</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schwartz]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Steg]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Szarek]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bhatt]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bittner]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Diaz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alirocumab and cardiovascular outcomes after acute coronary syndrome]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2018</year>
<volume>379</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>2097-107</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sabatine]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Giugliano]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Keech]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Honarpour]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Wiviott]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Murphy]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2017</year>
<volume>376</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>1713-22</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Toth]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Patti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Giglio]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Nikolic]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Castellino]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Rizzo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of statin intolerance in 2018: still more questions than answers]]></article-title>
<source><![CDATA[Am J Cardiovasc Drugs]]></source>
<year>2018</year>
<volume>18</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>157-73</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alsheikh-Ali]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Maddukuri]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Han]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Karas]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2007</year>
<volume>50</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>409-18</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ridker]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Pradhan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[MacFadyen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Libby]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Glynn]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2012</year>
<volume>380</volume>
<numero>9841</numero>
<issue>9841</issue>
<page-range>565-71</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Waters]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ho]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Boekholdt]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[DeMicco]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Kastelein]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Messig]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2013</year>
<volume>61</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>148-52</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mansi]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Frei]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Mortensen]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Statins and new-onset diabetes mellitus and diabetic complications: a retrospective cohort study of US healthy adults]]></article-title>
<source><![CDATA[J Gen Intern Med]]></source>
<year>2015</year>
<volume>30</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1599-610</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sattar]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Preiss]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Murray]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Welsh]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Buckley]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[de Craen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2010</year>
<volume>375</volume>
<numero>9716</numero>
<issue>9716</issue>
<page-range>735-42</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shepherd]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Blauw]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Murphy]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hyland]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Jukema]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kamper]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2002</year>
<volume>360</volume>
<numero>9346</numero>
<issue>9346</issue>
<page-range>1623-30</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baigent]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Keech]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kearney]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Blackwell]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Buck]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Pollicino]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90.056 participants in 14 randomised trials of statins]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2005</year>
<volume>366</volume>
<numero>9493</numero>
<issue>9493</issue>
<page-range>1267-78</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jacobson]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[NLA Task Force on Statin Safety: 2014 update]]></article-title>
<source><![CDATA[J Clin Lipidol]]></source>
<year>2014</year>
<volume>8</volume>
<numero>3^sSuppl</numero>
<issue>3^sSuppl</issue>
<supplement>Suppl</supplement>
<page-range>S1-4</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
